Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001810512 | Lung | AIS | peptidyl-serine phosphorylation | 60/1849 | 315/18723 | 4.75e-07 | 3.64e-05 | 60 |
GO:001820912 | Lung | AIS | peptidyl-serine modification | 61/1849 | 338/18723 | 2.49e-06 | 1.41e-04 | 61 |
GO:000038112 | Lung | AIS | regulation of alternative mRNA splicing, via spliceosome | 19/1849 | 60/18723 | 2.77e-06 | 1.52e-04 | 19 |
GO:001821012 | Lung | AIS | peptidyl-threonine modification | 30/1849 | 125/18723 | 3.29e-06 | 1.74e-04 | 30 |
GO:004277011 | Lung | AIS | signal transduction in response to DNA damage | 37/1849 | 172/18723 | 4.17e-06 | 2.13e-04 | 37 |
GO:190290313 | Lung | AIS | regulation of supramolecular fiber organization | 66/1849 | 383/18723 | 5.01e-06 | 2.45e-04 | 66 |
GO:001810712 | Lung | AIS | peptidyl-threonine phosphorylation | 28/1849 | 116/18723 | 6.14e-06 | 2.82e-04 | 28 |
GO:001063913 | Lung | AIS | negative regulation of organelle organization | 61/1849 | 348/18723 | 6.53e-06 | 2.92e-04 | 61 |
GO:003311913 | Lung | AIS | negative regulation of RNA splicing | 11/1849 | 25/18723 | 1.02e-05 | 4.19e-04 | 11 |
GO:000038012 | Lung | AIS | alternative mRNA splicing, via spliceosome | 21/1849 | 77/18723 | 1.19e-05 | 4.71e-04 | 21 |
GO:005149412 | Lung | AIS | negative regulation of cytoskeleton organization | 33/1849 | 163/18723 | 4.95e-05 | 1.43e-03 | 33 |
GO:004325413 | Lung | AIS | regulation of protein-containing complex assembly | 68/1849 | 428/18723 | 5.51e-05 | 1.56e-03 | 68 |
GO:005125813 | Lung | AIS | protein polymerization | 51/1849 | 297/18723 | 6.29e-05 | 1.70e-03 | 51 |
GO:190290413 | Lung | AIS | negative regulation of supramolecular fiber organization | 33/1849 | 167/18723 | 8.14e-05 | 2.03e-03 | 33 |
GO:000838013 | Lung | AIS | RNA splicing | 68/1849 | 434/18723 | 8.50e-05 | 2.11e-03 | 68 |
GO:000647611 | Lung | AIS | protein deacetylation | 23/1849 | 101/18723 | 1.06e-04 | 2.54e-03 | 23 |
GO:003227113 | Lung | AIS | regulation of protein polymerization | 41/1849 | 233/18723 | 1.85e-04 | 3.83e-03 | 41 |
GO:004351611 | Lung | AIS | regulation of DNA damage response, signal transduction by p53 class mediator | 11/1849 | 34/18723 | 2.82e-04 | 5.30e-03 | 11 |
GO:004677711 | Lung | AIS | protein autophosphorylation | 39/1849 | 227/18723 | 4.30e-04 | 7.37e-03 | 39 |
GO:003560111 | Lung | AIS | protein deacylation | 23/1849 | 112/18723 | 5.25e-04 | 8.42e-03 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYRK1A | SNV | Missense_Mutation | | c.217G>C | p.Asp73His | p.D73H | Q13627 | protein_coding | deleterious(0) | benign(0.364) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DYRK1A | SNV | Missense_Mutation | | c.1744C>G | p.His582Asp | p.H582D | Q13627 | protein_coding | tolerated_low_confidence(0.18) | possibly_damaging(0.84) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DYRK1A | SNV | Missense_Mutation | | c.1976N>T | p.Ser659Phe | p.S659F | Q13627 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.962) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK1A | SNV | Missense_Mutation | | c.1626C>A | p.Phe542Leu | p.F542L | Q13627 | protein_coding | tolerated(0.05) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DYRK1A | SNV | Missense_Mutation | | c.161N>T | p.Ser54Phe | p.S54F | Q13627 | protein_coding | deleterious_low_confidence(0.01) | benign(0.044) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
DYRK1A | SNV | Missense_Mutation | | c.46C>T | p.Arg16Trp | p.R16W | Q13627 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.454) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
DYRK1A | SNV | Missense_Mutation | | c.492G>C | p.Leu164Phe | p.L164F | Q13627 | protein_coding | deleterious(0.02) | probably_damaging(0.949) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
DYRK1A | SNV | Missense_Mutation | | c.2230N>C | p.Asp744His | p.D744H | Q13627 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.99) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
DYRK1A | SNV | Missense_Mutation | | c.183G>C | p.Gln61His | p.Q61H | Q13627 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.626) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DYRK1A | SNV | Missense_Mutation | | c.1898A>G | p.Tyr633Cys | p.Y633C | Q13627 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.984) | TCGA-E2-A15E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme1WO2011135259 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme15-1 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme23MPPDerivatives | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 249565842 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme13INDY | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | inhibitor | 405560505 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme4Upper | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme12-3 | | |
1859 | DYRK1A | DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE | | PMID28766366-Compound-Scheme18 | | |